Neogen Corp

Neogen Corp(NEOG)股票分析

$11.810

-0.443 (-3.75%)收盤時

Loading chart…
最高
12.380
開盤
12.380
成交量加權均價
11.96
成交量
2.46M
市值
3.46B
最低
11.685
成交金額
29.40M
企業價值/稅息折舊攤銷前利潤(TTM)
29.40

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.

AI 分析 of Neogen Corp (NEOG)

買進

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, and a significant improvement in financial performance, including a net loss reduction to $11.3 million in Q4 from a $612.2 million loss last year. Additionally, the stock has shown a year-to-date increase of 69.29%, indicating strong momentum. However, the main risk is the recent FDA warning that caused a 7.22% drop in shares, highlighting product safety concerns.

分析師評級(7)

-30.82% 下跌空間
持有
0 買進
7 持有
0 賣出
目前: 11.81
最低
6.50
平均
8.17
最高
10.00

Guggenheim

2026-09-30

目標價

$14

買進

Guggenheim

2026-09-29

目標價

$12

買進

Piper Sandler

2026-08-26

目標價

$14

增持

Piper Sandler

2026-08-03

目標價

$13

中性

Guggenheim

2026-01-09

目標價

$12

買進

估值指標

Neogen Corp(NEOG)目前預期本益比為 16.00,5 年平均預期本益比為 31.44。

預期本益比

合理
5 年均值 P/E
31.44
目前P/E
16.00
高估
47.00
低估
15.88

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
16.73
目前EV/EBITDA
29.40
高估
25.26
低估
8.20

預期股價營收比

合理
5 年均值 P/S
3.61
目前P/S
3.03
高估
5.33
低估
1.89

Alphio AI 對 NEOG 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NEOG

$7.55

情境價格

基

基準

基準 · 50%NEOG

$6.69

情境價格

悲

悲觀

悲觀 · 25%NEOG

$6.11

情境價格

持有 NEOG 的大戶

G

Gates Capital Management, Inc.

+ 持有NEOG

-7.42%

3個月報酬率

事件時間軸

2026-10-07 (ET)

16:30:00

Major Averages Decline After Fed Meeting Minutes Release

12:30:00

Major Averages Broadly Lower as 10-Year Treasury Yield Rises to 5.356%

09:00:00

Stock Futures Point to Lower Open as Tech Stocks Weigh

2026-10-06 (ET)

20:00:00

Nasdaq and S&P 500 Hit Record Highs

16:30:00

Raises FY27 Adjusted EBITDA Outlook to $181M-$183M

資訊

NEOG 常見問題 —— 由 Alphio AI 解答

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, and a significant improvement in financial performance, including a net loss reduction to $11.3 million in Q4 from a $612.2 million loss last year. Additionally, the stock has shown a year-to-date increase of 69.29%, indicating strong momentum. However, the main risk is the recent FDA warning that caused a 7.22% drop in shares, highlighting product safety concerns.

7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易